FORM PTO 1449 (modified)				АТ	ATTY DOCKET NO. APPLICATION NO. 10/808,522			322		
U.S. DEPARTMENT OF COMMERCE PATENT AND THAD EMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S)			AF	APPLICANT						
(Use several sheets if necessely)				WEI LIU ET AL.						
Nov 1 7 2004 5			-	March 25, 2004		GROUP 10	1645			
U.S. PATENT DOCUMENTS								<del></del>		
'EXAMINER INITIAL NUMBER DATE		DATE	·	NAME		SUBCLASS	FILING DATE IF APPROPRIATE			
6,506,559				Fire et al.	<u> </u>					
FOREIGN PATENT DOCUMENTS										
		DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT		
$\mathcal{C}$	wo	01/38503 A2	05/31/01	-	PCT			ENGLISH		
*	wo	02/053749 A2	07/11/02		PCT			ENGLISH		
V			OTHER DOCUMEN	T(S) (Inc	cluding Author, Title, Date, Pertinent Pages, Etc.)					
4		Altafaj, X. et al. transgenic mic Hum. Mol. Gen	e overexpres	sing	ental delay, motor abnormalities Dyrk1a (minibrain), a murine mo 5-23 (2001)	and co del of D	gnitive def own's synd	icits in drome,"		
		Arts, G-J. et al., "Adenoviral Vectors Expressing siRNAs for Discovery and Validation of Gene Function," Genome Res., Vol. 13, pp. 2325-32 (2003).								
		Bairoch, A. and Claverie, J-M., "Sequence patterns in protein kinases," Nature, Vol. 331, p.22 (Jan. 1988)								
		Bass, B.L., "RNA Interference: The Short Answer," Nature, Vol. 411, No. 6836, pp. 428-29 (May 2001).								
		Bockamp, E. et al., "Of Mice and Models: Improved Animal Models for Biomedical Research," Physiol. Genomics, Vol. 11, No. 3, pp. 115-32 (Dec. 2002).								
		Bolse, L.H. et al., "bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death," Cell, Vol. 74, pp. 597-608 (Aug. 1993)								
		Charbonneau, H. and Tonks, N.K., "1002 protein phosphatases?," Annu. Rev. Cell Biol., Vol. 8, pp.463-93 (1992)								
		D'Orazi, G. et al., "Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis," Nat. Cell Biol., Vol. 4, pp. 11-19 (Jan. 2002)								
		Duman, R.S. et al., "Neural plasticity to stress and antidepressant treatment," Biol. Psychiatry, Vol 46, pp.1181-91 (1999)								
		Dumas, J., "Growth factor receptor kinase inhibitors: recent progress and clinical impact," Curr. Opin. Drug Discov. Devel., Vol. 4, pp.378-89 (2001)								
			-		The pathway to signal achieveme	ent," Na	ture, Vol. 3	65, pp.781-		
		Elbashir, S.M. e	t al., "Duple ls," Nature.	kes of /ol. 4	7 21-Nucleotide RNAs Mediate RN 11, No. 6836, pp. 494-98 (May 200	NA Inter	ference in	Cultured		
4	Elbachiz C M et al. "Eurotional Anatomy of ciPNAs for Mediating Efficient DNAi in Decembile									
					adult brain," J. Neurosci., Vol. 2			2002)		
EXAMINER		PRIMA	RY EXAMINER		DATE CONSIDERED		1 8 2006			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S) (Use several sheets if necessary)  MOV 1 7 2004				ATTY DOCKET NO. 01997.001800 APPLICATION NO. 10/808,522							
				APPLICANT WEI LIU ET AL.							
				FILING DATE GROUP				 645			
ļ	\40	<del>]</del>		March 25, 2004	<del></del> _			<del></del>			
*EVAMINED	DOSAMENT NUMBER		U.S. P/	ATENT DOCUMENTS				FILING DATE			
INITIAL	*EXAMINER DOBUMENT NUMBER DATE			NAME			SUBCLASS	FILING DATE IF APPROPRIATE			
		<u> </u>	FOREIGN	PATENT DOCUMENTS		!					
	DOCUMENT DATE NUMBER			COUNTRY			SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT			
	<u> </u>	OTHER DOCU	MENT(S) (Inclu	ding Author, Title, Date, Pertinent Page	s, Etc.)						
	Galderisi, U. 181, No. 2, p		sense Olig	onucleotides as Therape		," J.	Cell Phy	siol., Vol.			
	Gao, G. et al protein kina	., "Non-catal se," J. Biol. (	lytic beta- Chem., Vo	and gamma-subunit iso1 1. 271, pp. 8675-81 (Apr. '	forms of the 1996)	5'-A	MP-activ	ated			
	Haribabu, B. et al., "Human calcium-calmodulin dependent protein kinase I: cDNA cloning, domain structure and activation by phosphorylation at threonine-177 by calcium-calmodulin dependent protein kinase I kinase," EMBO J., Vol. 14, pp. 3679-86 (1995)										
	Heasman, J. 209-14 (Mar.	Heasman, J., "Morpholino Oligos: Making Sense of Antisense?," Dev. Biol., Vol. 243, No. 2, pp. 209-14 (Mar. 2002).									
	Himpel, S. e DYRK1A," J	Himpel, S. et al., "Specificity determinants of substrate recognition by the protein kinase DYRK1A," J. Biol. Chem., Vol. 275:2431-38 (Jan. 2000)									
	Hofmann, T.G. et al., "Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2," Nat. Cell Biol., Vol. 4, pp. 1-10 (Jan. 2002) (plus one page supplementary information).										
	Hofmann, T.G. et al., "Human homeodomain-interacting protein kinase-2 (HIPK2) is a member of the DYRK family of protein kinases and maps to chromosome 7q32-q34," Biochimie, Vol. 82: 1123-27 (2000)										
	Hunter, T., "The role of tyrosine phosphorylation in cell growth and disease," Harvey Lect., Vol. 94, pp. 81-119 (1998-99)										
		Jacobs, B.L. et al., "Adult brain neurogenesis and psychiatry: a novel theory of depression," Mol. Psychiatry, Vol. 5, pp.262-69 (2000)									
	Kaur, G. et a flavone L86-	Kaur, G. et al., "Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275," J. Natl. Cancer Inst., Vol. 84, pp.1736-40, (1992)									
	Kim, Y.H. et for homeodo	Kim, Y.H. et al., "Homeodomain-interacting protein kinases, a novel family of co-repressors for homeodomain transcription factors," J. Biol. Chem., Vol. 273, pp. 25875-79 (Oct. 1998)									
		Levitzki, A. and Gazit, A., "Tyrosine kinase inhibition: an approach to drug development," Science, Vol. 267, pp. 1782-88 (Mar. 1995)									
4	Li, B. et al., "prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas," J. Biol. Chem., Vol. 271, pp.19402-08 (Aug. 1996)										
EXAMINER	Sł	TERIDAN SWOPE	, PH.D.	DATE CONSIDERED	JUL	1 8	3 2006				

<sup>\*</sup>EXAMINER: tritial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



	TA TRADERS		T		<del></del>	_=	<del></del> _			
FORM PTO 1449 (modified)  U.S. DEPARTMENT OF COMMERCE				TY DOCKET NO. 01997.001800	APPLI	APPLICATION NO. 10/808,522				
PATENT AND TRADEMARK OFFICE  LIST OF REFERENCES CITED BY APPLICANT(S)  (Use several sheets if necessary)			API	APPLICANT WEI LIU ET AL.						
(000 000 000 000 000 000 000 000 000 00				FILING DATE March 25, 2004			GROUP 1645			
		r <del></del>	U.S. 1	PATENT DOCUMENTS	· ·		<del>1 1</del>			
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	-	NAME CLASS S				FILING DATE IF APPROPRIATE		
010		. OTHER DOCU	MENT/S\ /lad	tuding Author Title Parkingst Page 1	e Etal					
<b>X</b>		et al., "The F	Protein K	uding Author, Title, Date, Pertinent Page inase Complement of the 1021		ome	e," Scienc	e, Vol.		
	298, pp. 1912-16, 1933-34 (Dec. 2002).  Micklefield, J., "Backbone Modification of Nucleic Acids: Synthesis, Structure and Therapeutic Applications," Curr. Med. Chem., Vol. 8, No. 10, pp. 1157-79 (Aug. 2001).									
	Paddison, P.J. et al., "Stable Suppression of Gene Expression by RNAi in Mammalian Cells," Proc. Natl. Acad. Sci. USA, Vol. 99, pp. 1443-48 (Feb. 2002)									
	Reynolds, A. et al., "Rational siRNA design for RNA interference," Nat. Biotechnol., Vol. 22, 326-30 (Mar. 2004)									
ì	Rochat-Steiner, V. et al., "FIST/HIPK3: a Fas/FADD-interacting serine/threonine kinase that induces FADD phosphorylation and inhibits fas-mediated Jun NH(2)-terminal kinase activation," J. Exp. Med., Vol. 192, pp.1165-74 (Oct. 2000)									
	Sioud, M., "Nucleic Acid Enzymes as a Novel Generation of Anti-gene agents," Curr. Mol. Med. Vol. 1, pp. 575-88 (2001)									
	Song, E. et al., "RNA interference Targeting Fas Protects Mice from Fulminant Hepatitis," Nat. Med., Vol. 9, pp. 347-51 (Mar. 2003)									
	Sridhar, R. et al., "Protein kinases as therapeutic targets," Pharm. Res., Vol. 17, pp. 1345-53 (2000)									
	Sui, G. et al., "A DNA Vector-based RNAi Technology to Suppress Gene Expression in Mammalian Cells," Proc. Natl. Acad. Sci. USA, Vol. 99, pp. 5515-20 (Apr. 2002)									
	Tejedor, F. et al., "minibrain: a new protein kinase family involved in postembryonic neurogenesis in Drosophila," Neuron, Vol. 14, pp. 287-301 (Feb. 1995)									
	Turek, T.C. et al., "Development and validation of a competitive AKT serine/threonine kinase fluorescence polarization assay using a product-specific anti-phospho-serine antibody," Anal Biochem., Vol. 299, pp. 45-53 (2001)									
	Wolfer, D.P. et al., "Knockout mice: simple solutions to the problems of genetic background and flanking genes," Trends Neurosci., Vol. 25, pp. 336-40 (Jul. 2002)									
	Xia, Z. et al., transcription (Sep. 1996)	"Calcium in by a MAP ki	flux via t inase/ER	he NMDA receptor induce K-dependent mechanism	es immediate ," J. Neuroso	e ea :i., \	rly gene /ol. 16, pp	o. 5425-36		
	Mammalian (	Cells," Proc.	Natl. Aca	by Expression of Short-in ad. Sci. USA, Vol. 99, pp. 6	terfering RN 6047-52 (Apr.	As a	and Hairpi 02)	in RNAs in		
EXAMINER		RIDAN SWOPE, RIMARY EXAMIN		DATE CONSIDERED	JU	<u>L</u> 1	L 8 2006	•		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 3 of 3

<del>/</del>							_	<del></del>		
FORM PTO 1449 (modified)				ATT	Y DOCKET NO.	APPL	APPLICATION NO. 10/808,522			
U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				<u> </u>	01997.001800		10/808,522			
OST OF RESERVED STREET OF RESERVED BY APPLICANT(S) (Ose several sheets if necessary)			APP	WEI LIU ET AL.						
FEB 2 4 2005				FILIÍ	NG DATE March 25, 2004		GROUP <b>1645</b>			
73		\$/		U.S. P	ATENT DOCUMENTS			-		
EXAMPLE INITIAL	MADEMAR	DOCUMENT NUMBER	DATE		NAME		ASS	SUBCLASS	FILING DATE IF APPROPRIATE	
	Γ			FOREIGN	PATENT DOCUMENTS	<del>- 1</del>		т		
		DOCUMENT NUMBER	DATE		COUNTRY		ASS	SUBCLASS	TRANSLATION YES/NO/ OR ABSTRACT	
7	wo	02/083709A	10/24/02	<del></del>	РСТ					
4	wo	2004/006838A	01/22/04		РСТ					
V					·					
					· ·					
	<u> </u>				iding Author, Title, Date, Pertinent Page					
ST		DATABASE EMBL Human genomic sequence of clone CTC-492K19, XP002293537, Database accession No. AC010271 (Sept. 17, 1999)(2 pgs.)								
		DATABASE EMBL Mouse genomic sequence of clone RP23-359H6, XP002293536, Database accession No. AC073767 (July 6, 2000)(52 pgs.)								
		DATABASE UNIPROT 'Online! HIPK4, XP002293538, Database accession No. Q8NE63 (Oct. 1, 2002)(2 pgs.)								
		DATABASE UNIPROT 'Online! Serine-threonine kinase from macaca, XP002293535, Database accession No. Q8WP28 (Mar. 1, 2002)(2 pgs.)								
		DATABASE OMIM NCBI; Review concerning HIPK1, XP002293539, Database accession No. 608003 (2 pgs.)								
V		DATABASE OMIM NCBI; Review concerning HIPK2, XP002293540, Database accession No. 606868 (2 pgs.)								
							<del></del> -			
EXAMINER	EXAMINER SHERIDAN SWOPE, PH.D. PRIMARY EXAMINER DATE CONSIDERED  JUL 18 2006									

Sheet\_1\_ of \_1\_

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with +-MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.